Amgen Can't Stop Avastin Biosimilar 'Patent Dance' After Opting In, Genentech Says
Executive Summary
Genentech seeks court order requiring Amgen to provide biosimilar manufacturing info so it can evaluate potential infringement; Supreme Court to hear Zarxio case on April 26.
You may also be interested in...
Biosimilar Litigation: Genentech Avastin Suit Tossed; Janssen Remicade Case Uncertain
US court dismisses Genentech suit over Amgen's patent dance moves; Janssen v. Celltrion trial is postponed as parties fight over Janssen's standing to sue; and Amgen wants to bar AbbVie citizen petition filers from seeing its Amjevita information.
Biosimilar Litigation: Genentech Avastin Suit Tossed; Janssen Remicade Case Uncertain
US court dismisses Genentech suit over Amgen's patent dance moves; Janssen v. Celltrion trial is postponed as parties fight over Janssen's standing to sue; and Amgen wants to bar AbbVie citizen petition filers from seeing its Amjevita information.
Biosimilars In 2017: Crowded US FDA Review Queue, Key Legal Decisions
At least five biosimilars could gain US licensure in the coming year on first-cycle review, including subsequent competitors to Remicade and Humira; however, patent litigation is expected to increase and will continue to slow the march of products from FDA approval to commercialization.